{
  "@context": {
    "bioagents": "https://bio.agents/ontology/",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "dct": "http://purl.org/dc/terms/",
    "edam": "http://edamontology.org/",
    "owl": "http://www.w3.org/2002/07/owl#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://doi.org/10.1093/BIB/BBAA312",
      "@type": "sc:CreativeWork"
    },
    {
      "@id": "https://bio.agents/acpredstackl",
      "@type": "sc:SoftwareApplication",
      "dct:conformsTo": "https://bioschemas.org/profiles/ComputationalAgent/0.6-DRAFT",
      "sc:additionalType": "Web application",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3379"
        },
        {
          "@id": "edam:topic_2640"
        },
        {
          "@id": "edam:topic_3474"
        },
        {
          "@id": "edam:topic_0121"
        },
        {
          "@id": "edam:topic_0154"
        }
      ],
      "sc:citation": [
        "pubmed:33316035",
        {
          "@id": "https://doi.org/10.1093/BIB/BBAA312"
        }
      ],
      "sc:description": "ACPredStackL  is a ensemble learning framework using stacking strategy for accurate identification of ACPs.\nAnticancer peptides (ACPs),known as potential future therapeutics for cancer, have been studied extensively,attribution to their unique ability to target cancer cells without affecting healthy cells directly.Many peptide-based drugs are currently being evaluated in preclinical and clinical trial.",
      "sc:featureList": [
        {
          "@id": "edam:operation_3900"
        },
        {
          "@id": "edam:operation_3631"
        },
        {
          "@id": "edam:operation_3936"
        }
      ],
      "sc:name": "ACPredStackL",
      "sc:url": "http://bigdata.biocie.cn/ACPredStackL/"
    }
  ]
}